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CC BY-NC-ND license (http://creativeBackground: To investigate the incidence and risk factors for the occurrence of proven or prob-
able invasive fungal infection (IFI) in adult patients receiving allogeneic hematopoietic stem
cell transplantation (HSCT).
Methods: We retrospectively analyzed 421 patients undergoing HSCT between 2002 and 2013 in
our hospital. The risk factors for the occurrence of IFI were analyzed using Cox regression
models.
Results: Thirty-one patients with the median age of 42 years (range, 19e60 years) developed
IFI after HSCT. The post-HSCT IFI incidence was 7.4% and median time from HSCT to the diag-
nosis of IFI was 139 days (range, 2e1809 days). Of the pretransplant factors, European Group
for Blood and Marrow Transplantation (EBMT) risk score > 2 (pZ 0.001) and prior history of IFI
(p Z 0.006) or type 2 diabetes mellitus (DM; p Z 0.042) were the significant predictors forematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Number 201,
Taiwan.
.tw (J.-P. Gau).
.01.002
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568 Y.-C. Liu et al.post-HSCT IFI in univariate analyses. In multivariate analysis, EBMT risk score > 2 (p Z 0.015)
and prior history of IFI (pZ 0.006) retained significance. Of the post-transplant factors, acute
graft-versus-disease (GVHD) overall Grade IIIeIV (p < 0.001), extensive chronic GVHD
(p Z 0.002), development of post-transplant lymphoproliferative disorders (p Z 0.005), and
the use of high-dose steroids (p < 0.001) were statistically significant in univariate analyses.
After multivariate analysis, high-dose steroids (p < 0.001) and acute GVHD overall Grade III
eIV (p Z 0.045) retained significance.
Conclusion: These results suggest that risk group stratification prior to HSCT and monitoring of
IFI in patients with severe GVHD receiving high-dose steroids is mandatory to reduce the mor-
tality and morbidity of post-HSCT IFI, especially in those with prior history of IFI.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Invasive fungal infection (IFI), especially aspergillosis, is a
serious complication following hematopoietic stem cell
transplant (HSCT) and can cause significant morbidity and
mortality in recipients of the procedure.1,2 Recent studies
have demonstrated that routine prophylactic use of flu-
conazole during HSCT decreased the risk of invasive
candidiasis to a low incidence of 1.1e5%.2e6 On the con-
trary, increasing incidence of invasive mold infection has
been reported in recent series.7,8 Analyses of The
Transplant-Associated Infection Surveillance Network
(TRANSNET) database showed that the cumulative annual
incidence of IFIs were 7.7, 8.1, 5.8, and 1.7 in every 100
transplants for matched-unrelated allogeneic, mismatch-
related allogeneic, matched-related allogeneic, and
autologous HSCT, respectively.2 In the TRANSNET database,
the estimated post-HSCT 1-year survivals of invasive
candidiasis and invasive aspergillosis are only 33% and 25%,
respectively.2 In the other prospective study, high post-
HSCT mortality in invasive candidiasis, about 49% at
12 weeks, was also noted.9
IFI may occur during the pre-engraftment neutropenic
period, the early postengraftment period or in the late
postengraftment period after Day þ100.10,11 The reported
risk factors for IFI after HSCT include transplant type, use
of antifungal prophylaxis, conditioning regimen, compat-
ibility of human leukocyte antigen between donor and
recipient, cytotoxic conditioning therapy-related intesti-
nal mucosal damage, stem cell source, and disease sta-
tus.7,11e13 In addition, other important recipient-related
factors were age at HSCT, duration of pre-engraftment
neutropenia, graft failure or rejection, the severity of
acute and chronic graft-versus-host disease (GVHD), use of
steroids, the presence of cytomegalovirus (CMV) infec-
tion, and geoclimatic factor.5,7,11e14 Taiwan is located in
Southeastern Asia with generally hot and wet climatic
condition. It is presumed that patients receiving HSCT
here may have an increased incidence of IFI. Our study
attempts to look at the incidence of IFI after HSCT in a
single medical center of Taiwan and to explore the asso-
ciated risk factors and the final outcome after the
infection.Materials and methods
Study patient population
We retrospectively reviewed themedical records of 421 adult
patients (age  18 years) who received allogeneic HSCT be-
tweenJanuary1,2002andDecember31,2013 intheBloodand
MarrowTransplant Center of Taipei VeteransGeneral Hospital
in Taipei, Taiwan. Transplant-related clinical data including
age, gender, disease diagnosis, type of transplant, human
leukocyte antigen (HLA) matching, conditioning regimen,
GVHD, and other clinical complications were all retrospec-
tively collected. For those undergoing multiple transplants,
only the data pertinent to the last procedure were included.
The retrospective review of medical records was approved by
the Institutional Ethical Committee in agreement with the
Helsinki Declaration of 1975, revised in 2008.
Transplant details and conditioning regimens
HLA-typing tests of low to intermediate resolution for six or
eight alleles (HLA-A, -B, -DR, or -C) were performed to
select donors for allogeneic HSCT. Donor’s types included
sibling donor, matched unrelated marrow, haploidentical
donor (father or mother) or umbilical cord blood. Accord-
ingly, patients were categorized into the fully matched
group or mismatched group. Myeloablative conditioning
regimens including busulfan combined with cyclophospha-
mide, or total body irradiation of 1200 cGy combined with
cyclophosphamide. Fludarabine-based nonmyeloablative
conditioning regimens were administered to elderly pa-
tients or those with comorbidities.
Antifungal prophylaxis, monitoring, and treatment
Standard antifungal prophylaxis with fluconazole was star-
ted on initiation of conditioning till the end of neutropenia.
From 2010 onwards, echinocandin, such as micafungin or
caspofungin, was given to patients with history of pre-
transplant fungal infection, intolerance to fluconazole
toxicity, high EBMT risk score, or as the clinical physician’s
option.
Post-HSCT fungal infection in adults 569From October 2009 onwards, galactomannan (GM) anti-
gen assay was performed for clinical suspicion of IFI at our
hospital. For those pre- or post-transplant patients with
positive GM test and clinically suspicious fungal infection
based on symptoms and imaging studies, medications
against Aspergillus infection were given for prophylaxis or
treatment.
Empirical antifungal therapy with voriconazole or lipo-
somal amphotericin-B were used in post-transplant patients
with diagnosis of aspergillosis, or invasive yeast infection.
Voriconazole, posaconazole, or liposomal amphotericin-B
were not used as routine antifungal prophylaxis.
GVHD prophylaxis and treatment
Standard protocol including cyclosporine and short-term
low dose methotrexate were adopted for GVHD prophy-
laxis. In addition, recipients of unrelated donor transplants
also received rabbit antithymocyte globulin. Severity of
acute GVHD (aGVHD) was graded according to the system
developed by Glucksberg and Thomas and the severity of
the chronic GVHD (cGVHD) in each organ was determined
according to NIH scoring system.15,16 Patients that devel-
oped aGVHD > functional overall Grade II, extensive
cGVHD, or alloimmune lung disease would usually receive
high-dose methylprednisolone 1e2 mg/kg/d.
Transplantation risk evaluation
According to the age at HSCT, disease stage prior trans-
plantation, time interval from diagnosis to transplant,
donor type, and donor recipient sex combination, we
retrospectively calculated transplantation risk for all study
patients based on EBMT risk scoring system.17 The EBMT risk
score was also used as a variable factor in our analysis.
Clinical evaluation and definitions
This retrospective review was to determine the incidence
of probable or proven IFI, according to the revised defini-
tions of European Organization for Research and Treatment
of Cancer (EORTC)/the National Institute of Allergy and
Infectious Diseases Mycoses Study Group (MSG) Consensus
Group.18 In addition to host factor, the probable IFI requires
the presence of both a clinical criterion and a mycological
criterion. In our study, patients with clinical criteria of IFI,
including typical signs on lung computed tomography, im-
ages showing sinonasal, or CNS infection, required supple-
mentary evidence from mycological criteria including
positive results from cytology, direct microscopic exami-
nations, or fungal culture or indirect test of the GM antigen
in plasma, serum, bronchoalveolar lavage fluid, or cere-
brospinal fluid. The proven IFI required proof of IFI by
demonstration of fungal elements by microscopic exami-
nation or positive results of fungal culture in diseased tissue
or blood.
Statistical analysis
Possible predictors for IFI were retrospectively analyzed
using Cox proportional hazard models. Factors withstatistical significance (p < 0.05) upon univariate analysis
were included inmultivariate analysis. Results are expressed
as hazard ratios and their corresponding 95% confidence in-
tervals (CIs). Age of 40 years was adopted as the cutoff value
based on median age at HSCT and the results of receiver
operating characteristic curve. For statistical analysis, SPSS
version 18.0 (SPSS Inc., Chicago, IL, USA) was used.
Results
Clinical characteristics of study patients
In total, 421 patients who received HSCT between January
2002 and December 2013 were analyzed. The median age at
HSCT was 40 years (range, 18-67 years). Hematological
malignancies comprised 88.4% (n Z 372) of indications for
HSCT and the other nonmalignant disease 11.6% (n Z 49).
Donor type included 208 matched sibling donors (49.4%),
203 unrelated donors (48.2%), eight haploidentical donors
(1.9%), and two umbilical cord blood donors (0.5%). Median
time of follow-up after HSCT was 445 days (range, 10e4434
days). The clinical characteristics of patients are summa-
rized in Table 1.
Incidence of IFI
The annual incidence of post-HSCT IFI between 2002 and
2013 presented with a bimodal pattern in our study (Fig. 1).
The overall cumulative IFI incidence was 7.4% (31/421),
including 23 (5.5%) proven and eight (1.9%) probable cases.
Median time from HSCT to the diagnosis of IFI was 139 days
(range, 2e1809 days). Sixteen of 31 patients were diag-
nosed with IFI prior to post-HSCT Day þ139 and the other 15
patients after Day þ139. In our study, 15 of 421 patients
(3.6%) had a history of IFI prior to HSCT. Among the 15
patients, four (26.6%) were diagnosed with recurrent IFI.
Among the 31 patients with IFI, nine were confirmed as
infection with Aspergillus spp. (29%), 17 with Candida spp.
(54.8%), and one patient (3.24%) each with Acremonium
spp, mucormycosis, Trichosporon asahii, unidentified
yeast, and Cryptococcus neoformans. We also adopted the
median time for all IFI as cutoff time point to define early-
and late-onset infection (occurring prior to or after Day
þ139). Invasive mold infection tended to occur late after
transplant with eight of 11 (73%) mold IFIs presenting as
late infection in contrast to seven of 20 (35%) in yeast IFI.
Regarding the pretransplant diagnosis of the 31 patients
with IFI, 16 (51.6%) were myeloid malignancies, 12 (38.7%)
had lymphoid malignancies and three had the diagnosis of
severe aplastic anemia.
Pretransplant predictors for the occurrence of IFI
A total of 256 patients were defined as high risk of trans-
plantation based on EBMT risk score > 2 at starting HSCT.
Among these patients, 26 (10.3%) developed IFI. Comparing
patients of early IFI with those of late onset, early IFI had a
higher proportion of patients with EBMT risk score > 2 [14/
16 (87.5%) versus 12/15 (80%)]. The median EBMT risk score
was 4 for the early IFI and was 3 for the late infection
Table 1 Clinical characteristics of study patients
(n Z 421)
Patient characteristics n %
Gender
Female 179 42.5
Male 242 57.5
Age at HSCT (y), median
 40 203 48.2
> 40 218 51.8
EBMT risk
 2 169 38.5
> 2 252 61.5
Indication for HSCT
AML/MDS 173 41.1
MPD 31 7.4
ALL 77 18.3
Lymphoma 64 15.2
MM 21 5.0
SAA 49 11.6
Other 6 1.4
Transplant number
1 379 90.0
Multiple 42 10.0
Prior history of IFI
Yeast 9 2.1
Mold 6 1.4
Donor type
MSD 208 49.4
Unrelated marrow 203 48.2
Haploidentical 8 1.9
Umbilical cord blood 2 0.5
Donor relation
Related 208 49.4
Unrelated 213 50.6
Conditioning regimen
TBI based 182 43.2
Chemobased 239 56.8
Myeloablative 276 65.6
Nonmyeloablative 145 34.4
Antifungal prophylaxis
Fluconazole 368 87.4
Echinocandin 53 12.6
Mycological detection of IFI
No detection 390 92.6
Yeast 20 4.8
Blood culture 17 4.0
Biopsy 2 0.5
BAL 1 0.3
Mold 11 2.6
GM in serum, BAL or CSF 9 2.1
Biopsy 2 0.5
ALL Z acute lymphoblastic leukemia; AML Z acute myeloid
leukemia; BAL Z bronchoalveolar lavage; CSF Z cerebrospinal
fluid; EBMT Z European Group for Blood and Marrow Trans-
plantation; GM Z galactomannan antigen assay;
HSCTZ hematopoietic stem cell transplantation; IFIZ invasive
fungal infection; MDS Z myelodysplastic syndromes;
MM Z multiple myeloma; MPD Z myeloproliferative disorders;
MSD Z matched sibling donor; MUD Z matched unrelated
donor; SAA Z severe aplastic anemia; TBI Z total body
irradiation.
Figure 1. The annual cumulative incidence of probable and
proven IFI. IFI Z invasive fungal infection.
570 Y.-C. Liu et al.subgroup. In addition, of all the patients in the study, only
19 (4.5%) patients had a prior history of type 2 DM before
transplantation. However, three of the 19 DM patients
(15.7%) developed IFI. In univariate analyses for age at
HSCT, EBMT risk score, gender, disease type, antifungal
prophylaxis, prior history of IFI or DM, conditioning
regimen, donor type, and numbers of transplantation, we
found that EBMT risk score > 2 (pZ 0.001) and prior history
of IFI (p Z 0.006) or DM (p Z 0.042) were the significant
predictors for IFI. After multivariate analysis, only EBMT
risk score > 2 (p Z 0.015) and a prior history of IFI
(p Z 0.006) retained significance. The analyses are
detailed in Table 2.
Post-transplant risk factors for the occurrence of
IFI
Acute GVHD was documented in 138 (32.9%) patients
including 22.8% with overall Grade IeII (n Z 96) and 9.98%
with overall Grade IIIeIV (nZ 42). The incidence of IFI was
3.2% (nZ 12) in patients with overall Grade IeII or absence
of aGVHD and 35.1% (n Z 19) in those with overall Grade
IIIeIV. In our study, 86.5% of patients (n Z 364) developed
no or only limited cGVHD and the other 13.5% of patients
(n Z 57) suffered from extensive cGVHD. In those with
extensive cGVHD, 21% of patients (nZ 12) developed IFI. In
addition, PTLD developed in 16 of the 421 patients (3.8%),
proven by pathological biopsy. Among the 16 patients with
PTLD, four (25%) developed IFI. High-dose methylprednis-
olone was used in GVHD, PTLD, or alloimmune lung disease.
Among the 54 patients (12.8%) receiving high-dose steroids,
subsequent IFI developed in 12 cases (35.1%). In univariate
analysis, aGVHD overall Grade IIIeIV (p < 0.001), extensive
cGVHD (pZ 0.002), PTLD (pZ 0.005), and the use of post-
transplant high-dose steroids (p < 0.001) were significantly
associated with post-HSCT IFI. After multivariate analysis,
only high-dose steroids (p < 0.001) and aGVHD overall
Grade IIIeIV (p Z 0.045) retained significance. The
Table 2 Possible factors for invasive fungal infection (IFI) after adult allogeneic hematopoietic stem cell transplantation
(HSCT)
Factors No. of
patients
IFI Univariate analysis Multivariate analysis
n % HR 95%CI p HR 95%CI p
Age at HSCT (y)
 40 203 10 4.9
> 40 218 21 9.6 1.548 0.757e3.164 0.231
EBMT risk scores
 2 169 5 2.9
> 2 252 26 10.3 5.038 1.930e13.151 0.001 3.390 1.273e9.029 0.015
Gender
Female 179 11 6.1
Male 242 20 8.2 1.412 0.676e2.947 0.359
Disease type
Myeloid 205 16 7.8
Nonmyeloid 216 15 6.9 0.859 0.424e1.739 0.672
Prophylaxis
Fluconazole 368 25 6.7
Echinocandin 53 6 11.3 2.326 0.938e5.769 0.069
Prior history IFI
No 406 27 6.6
Yes 15 4 26.6 4.457 1.551e12.806 0.006 5.807 1.675e20.129 0.006
Prior history DM
No 402 28 6.9
Yes 19 3 15.7 3.490 1.045e11.653 0.042
Conditioning
Nonmyeloablative 145 8 5.5
Myeloablative 276 2 8.3 1.592 0.712e3.561 0.258
Conditioning
Chemobased 239 19 7.9
TBI-based 182 12 6.5 0.799 0.388e1.646 0.543
Donor relation
Related 208 13 6.2
Unrelated 213 18 8.4 1.695 0.828e3.472 0.149
Transplant no.
One 379 27 7.1
Multiple 42 4 9.5 2.012 0.699e5.788 0.195
Donor type
MSD 208 13 6.2 1 x x
Unrelated donor 203 16 7.8 1.544 0.740e3.221 0.247
Haploidentical 8 1 12.5 4.713 0.612e36.294 0.137
UCB 2 1 50 x x x
aGVHD
No or Overall Gr. I-II 379 23 6.0
Gr. III-IV 42 8 19.0 6.936 3.046e15.796 <0.001 2.627 1.023e6.748 0.045
High steroids post SCT
No 367 12 3.2
Yes 54 19 35.1 11.148 5.401e23.008 <0.001 11.185 3.875e32.289 <0.001
cGVHD
No or limited 364 19 5.2
Extensive 57 12 21.0 3.131 1.518e6.459 0.002
CMV-reactivation
No 214 17 7.9
Yes 207 14 6.7 1.043 0.511e2.131 0.907
PTLD
No 405 27 6.6
Yes 16 4 25 4.627 1.607e13.320 0.005
Significant values (P < 0.05) are given in bold.
aGVHD Z acute GVHD; cGVHD Z chronic GVHD; CI Z confidence interval; CMV Z cytomegalovirus; DM Z Diabetes mellitus;
EBMT Z European Group for Blood and Marrow Transplantation; Gr. Z grade; GVHD Z graft-versus-host disease; HR Z hazard ratio;
MSD Z matched sibling donor; MUD Z matched unrelated donor; PTLD Z Post-transplant lymphoproliferative disorders. TBI Z total
body irradiation; UCB Z umbilical cord blood.
572 Y.-C. Liu et al.descriptions of HSCT complications and their relationships
to IFI are given in Table 2.
Outcome of the patients with post-HSCT IFI
The median age of the 31 patients with IFI was 42 years
(range: 19e60 years). Seventeen (54.8%) patients experi-
enced intensive care unit (ICU) care with a median of 8 days
staying at ICU (range, 2e96 days). In comparison to late-
diagnosed IFI, higher proportion of patients with early IFI
needed ICU care [10/16 (62.5%) vs. 7/15 (46.7%)] and pa-
tients with early mold infection had higher mortality rate
compared to late infection [3/3 (100%) vs. 4/8 (50%)]. The
death rate was all high in yeast infection whether the IFI
was diagnosed early [11/13 (85%)] or late [7/7 (100%)]. Only
19.4% (6/31) of patients with IFI survived while 56.4%
(n Z 220) of patients without IFI achieved long-term sur-
vival. The overall survival after HSCT was significantly
worse in IFI group as compared with the other patients (log-
rank p < 0.001; Fig. 2). The probability of OS was 82.1% at
Day þ100, 75.1% at Day þ180, and 64.9% at 1 year post-
transplantation for patients without IFI, compared with
74.2%, 54.8%, and 45.2%, respectively, in those with IFI. Of
the patients dying of IFI (n Z 25), death occurred in 17
(68%) patients prior to Day þ30 and in 22 (88%) patients
prior to Day þ90. The causes of death were a direct result
of IFI in 18 (58.1%) patients, complications associated with
IFI in three (9.7%) patients, and other unrelated causes such
as disease relapse, progressive GVHD, or other causes in
four (12.9%) patients.
Discussion
Our study demonstrated a 7.4% cumulative incidence of
probable and proven IFI within a period of 12 years in a
single Asian institute. The annual incidence curve presented
with a bimodal pattern with two peaks of high IFI incidence
rate in 2003 (14.3%) and 2011 (12.2%). The characteristic
variation cannot be well explained. However, gradually
increased patient age in recent years, accumulation ofFigure 2. Overall survival after HSCT.
HSCT Z hematopoietic stem cell transplantation.experience in HSCT, adoption of policy with routine anti-
fungal prophylaxis and advance in diagnostic technology
could lead to the unusual presentation. The median age at
HSCT was 39 years prior to 2005, which was younger when
compared to the median age of 43 years after 2008. Routine
use of antifungal prophylaxis could be the cause of
decreasing IFI incidence after 2003. Increasing patient age,
enhanced awareness of IFI, introduction of GM test for
diagnosis, and increased incidence of mold IFI could
contribute to the second peak since 2008, which sloped
down thereafter with increased use of echinocandin for
prophylaxis. Our observations are actually similar to a
recent report of IFI in a pediatric cohort.19 However, as
compared with the study prior to 2000, IFI rate has already
improved significantly (7.4% vs 15%).20 Consistent with pre-
vious reports, our study also found that the median time of
developing IFI after transplant is around Day þ100.5,11,21,22
Our study showed that a prior history of fungal infection
was a significant risk factor for IFI after transplantation.
This is in agreement with previous reports. Cornely et al23
described an increased risk of subsequent IFI and worse
outcomes in patients with a previous history of IFI. Another
preliminary analysis by Maziarz et al24 also described an
increased risk (24%) for subsequent IFI in patients with a
history of IFI prior to undergoing allogeneic HSCT. All these
observations suggest that constant vigilance should be
given to patients with history of pretransplant fungal
infection and monitoring recurrent IFI after the procedure
is mandatory. In a preliminary analysis, Maziarz et al24
described an increased risk for subsequent IFI and lower
1-, 3-, and 5-year disease-free survival and OS in patients
with a prior history of IFI undergoing allogeneic HSCT for
acute leukemia, myelodysplastic syndrome, and chronic
myelogenous leukemia. In our study, patients with hema-
tological malignancies (pZ 0.879, data not shown in Table
2) or nonmyeloid malignancies (pZ 0.672) did not have an
increased risk of subsequent IFI after HSCT. Our study also
confirmed that the occurrence of IFI was associated with a
pretransplant EBMT risk score > 2 (p Z 0.015). IFI
contributed to the causes of mortality in patients with a
high EBMT risk score. The result was also similar to pediatric
data and demonstrated an increased risk of IFI with a prior
determined HSCT treatment-related mortality risk > 20%.19
Post-HSCT risk factors including the use of high-dose ste-
roids, GVHD, and PTLD could be associated with IFI.
Consistent with previous reports,5,10,11,20,25 our study con-
firms that overall Grade IIIeIV aGVHD (p Z 0.045) is a sig-
nificant risk factor. In addition, PTLD was also an important
issue for IFI. The overall frequency of PTLD in our hospital
was 3.8% (16/421), which was similar to the results from a
large study.26 However, high incidence with a proportion up
to 25% (4/16) of the PTLD patients developed IFI. The as-
sociation was statistically significant (p Z 0.005) in uni-
variate analysis, but lost significance in multivariate
analysis, probably confounded by high-dose steroid use and
poor immunity. The small numbers of PTLD cases in our
study preclude further in-depth analysis. High-dose steroids
were often used for advanced aGVHD, extensive cGVHD, or
alloimmune lung disease.27,28 Our study also confirmed the
strong association between the use of high-dose steroids
and IFI, either in univariate (p < 0.001) or multivariate
analysis (p < 0.001).
Post-HSCT fungal infection in adults 573Previous studies reported that haploidentical HSCT had
an increased risk for opportunistic fungal infections (range,
7.1e24%) but pertinent data in this particular patient group
were limited.11,29,30 In our study, a relatively similar risk for
IFI in haploidentical HSCT (1/8; 12.5%) was noted. However,
the limited patient number of haploidentical HSCT
rendered statistics insignificant in terms of IFI. The
increased risk of IFI may be caused by delayed engraftment
and delayed immune reconstitution and GVHD in these
mismatched transplantation recipients.
Patients afflicted by IFI had high mortality rate, even
after correction for a priori determined EBMT risk.
Regarding the timing for IFI, in comparison to late yeast
infection (35%), invasive mold infection tended to occur
late after the transplant (73%). The observation was similar
to the findings in previous studies.2,3,7,31 In our study, the
median EBMT risk score in patients with IFI was high (> 2
points) with median risk Scores 4 and 3 for the early and
late IFI subgroups, respectively. In comparison to late-
diagnosed IFI, the early IFI subgroup had higher propor-
tion of patients with EBMT risk score > 2 (87.5%), necessity
of ICU care (62.5%), and higher mortality in patients with
mold infection (100%). Our standard prophylaxis using flu-
conazole is conceivably ineffective in preventing mold
infection. All three patients with mold infection occurring
prior to Day þ139 had received fluconazole prophylaxis.
They all died of the infection. Three of eight patients with
late-onset mold infection had received echinocandin pro-
phylaxis, which probably contributed to delaying onset of
the infection and improved outcome. Echinocandin agents
have been used increasingly for antifungal prophylaxis in
recent years; however, we did not observe any significant
reduction in the incidence of IFI as compared with the
standard fluconazole prophylaxis (p Z 0.069). When con-
fronting the challenge of invasive mold infection, in addi-
tion to the hematological recovery and prophylactic
antifungal agents, delayed immune reconstitution after
allogeneic HSCT also played an important role influencing
the poor survival of mold infection developing prior to Day
þ139.
In our study, based on diagnosing proven and probable
cases of IFI according to the standard definitions of EORTC/
MSG Consensus Group,18 we demonstrated the cumulative
incidence of IFI and clinical characteristics of post-
transplant IFI and identified advanced GVHD and use of
high-dose steroid as risk factors for IFI. Development of IFI
significantly jeopardizes survival after HSCT. Recognition of
patients with high risk stratification for IFI would allow
physicians to give effective prophylactic agents and vigi-
lantly monitor these patients to reduce the mortality and
morbidity associated with IFI.Conflicts of interest
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